ストックスクリーナーアプリを入手
8.99
4.90%
0.42
アフターアワーズ：
9.00
0.010
+0.11%
前日終値:
$8.57
開ける：
$8.76
24時間の取引高:
2.43M
Relative Volume:
0.75
時価総額：
$1.44B
収益：
$68.56M
当期純損益:
$-437.99M
株価収益率:
-2.8414
EPS:
-3.1639
ネットキャッシュフロー:
$-396.61M
1週間 パフォーマンス:
-3.54%
1か月 パフォーマンス:
-10.10%
6か月 パフォーマンス:
+73.55%
1年 パフォーマンス:
+29.35%
1日の値動き範囲:
$8.65
$9.39
1週間の範囲:
$8.51
$9.5483
52週間の値動き範囲:
$4.155
$10.94
Vir Biotechnology Inc Stock (VIR) Company Profile
名前
Vir Biotechnology Inc
セクター
電話
415-906-4324
住所
1800 OWENS STREET, SAN FRANCISCO, CA
Compare VIR vs VRTX, REGN, ALNY, ARGX, INSM
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
VIR
Vir Biotechnology Inc
|
8.99 | 1.37B | 68.56M | -437.99M | -396.61M | -3.1639 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Vir Biotechnology Inc Stock (VIR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-02-24 | アップグレード | Raymond James | Outperform → Strong Buy |
| 2025-09-03 | 開始されました | Evercore ISI | Outperform |
| 2025-08-27 | アップグレード | BofA Securities | Neutral → Buy |
| 2024-01-29 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2023-09-08 | ダウングレード | BofA Securities | Buy → Neutral |
| 2023-03-06 | アップグレード | JP Morgan | Neutral → Overweight |
| 2023-02-21 | アップグレード | Goldman | Neutral → Buy |
| 2023-01-27 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
| 2022-09-14 | 開始されました | SVB Leerink | Outperform |
| 2022-09-09 | 開始されました | Morgan Stanley | Underweight |
| 2022-03-03 | アップグレード | Robert W. Baird | Underperform → Neutral |
| 2021-12-21 | ダウングレード | Robert W. Baird | Neutral → Underperform |
| 2021-10-25 | アップグレード | JP Morgan | Underweight → Neutral |
| 2021-09-22 | ダウングレード | Goldman | Buy → Neutral |
| 2021-06-04 | 再開されました | Robert W. Baird | Neutral |
| 2021-01-27 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2021-01-20 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-10-05 | 開始されました | BofA Securities | Buy |
| 2020-09-14 | アップグレード | Goldman | Neutral → Buy |
| 2020-09-11 | アップグレード | JP Morgan | Underweight → Neutral |
| 2020-08-20 | 開始されました | Needham | Buy |
| 2020-03-19 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2020-03-13 | ダウングレード | Goldman | Buy → Neutral |
| 2020-02-27 | ダウングレード | Robert W. Baird | Neutral → Underperform |
| 2020-02-04 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2019-11-14 | 開始されました | Robert W. Baird | Neutral |
| 2019-11-05 | 開始されました | Barclays | Overweight |
| 2019-11-05 | 開始されました | Cowen | Outperform |
| 2019-11-05 | 開始されました | Goldman | Buy |
| 2019-11-05 | 開始されました | JP Morgan | Overweight |
すべてを表示
Vir Biotechnology Inc (VIR) 最新ニュース
Vir Biotechnology (NASDAQ:VIR) CAO Sells $70,324.32 in Stock - MarketBeat
Vir Biotechnology prices $150M stock offering - MSN
VIR SEC FilingsVir Biotechnology, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Insider Sell: Brent Sabatini Sells Shares of Vir Biotechnology I - GuruFocus
Vir Biotechnology (VIR) accounting chief sells 7,711 shares under plan - Stock Titan
Henry Schein, Vir Biotechnology, Ultra Clean Holdings and other big stocks moving higher on Tuesday - MSN
Vir Biotechnology (VIR) CFO restructures 5,000 shares via family trust transfer - Stock Titan
Insider sales at VIR (NASDAQ: VIR) include multiple February 2026 transactions - Stock Titan
Valuation Update: Is Vir Biotechnology Inc stock influenced by commodity prices2026 Sector Review & Verified Stock Trade Ideas - baoquankhu1.vn
Hudson Bay Capital Management LP Grows Position in Vir Biotechnology, Inc. $VIR - MarketBeat
These analysts boost their forecasts on Vir Biotechnology - MSN
Why did Vir Biotechnology stock surge 60% after-hours today? - MSN
Guidance Update: What is the Moat Score of Vir Biotechnology IncPortfolio Value Report & AI Forecast for Swing Trade Picks - baoquankhu1.vn
Vir Biotechnology, Inc. (NASDAQ:VIR) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Vir Biotechnology Stock Pre-Market (+0.2%): Ahead of Leerink Conference Presentation - Trefis
Biggest stock movers Tuesday: HIMS, VIR, CLVT, and more - MSN
VIR-5500 Phase 1 trial yields positive data in prostate cancer, Vir Biotechnology asserts - Traders Union
Vanguard Group Inc. Lowers Stock Position in Vir Biotechnology, Inc. $VIR - MarketBeat
Vir Biotechnology Q4 2025 earnings preview - MSN
HC Wainwright Brokers Boost Earnings Estimates for VIR - MarketBeat
Why Did Vir Biotechnology Stock Surge 60% After-Hours Today? - Stocktwits
Vir Biotechnology Names CEO Marianne De Backer as President - The Globe and Mail
According to the latest filing disclosed by the U.S. Securities and Exchange Commission (SEC), biotechnology company Vir Biotechnology, Inc. has announced a significant personnel appointment. - Bitget
Vir Biotechnology Appoints Marianne De Backer As President In Addition To CEO On March 4, 2026SEC Filing - TradingView
Vir Biotechnology appoints Marianne De Backer as president in addition to CEO on March 4, 2026SEC filing - marketscreener.com
Vir Biotechnology, Inc. Appoints Marianne De Backer as President - marketscreener.com
Vir Biotechnology (NASDAQ:VIR) Stock Price Expected to Rise, HC Wainwright Analyst Says - MarketBeat
VIR: HC Wainwright & Co. Raises Price Target to $20, Maintains B - GuruFocus
Assessing Vir Biotechnology (VIR) Valuation After Astellas Alliance And VIR-5500 Phase 1 Update - simplywall.st
Vir Biotechnology, Inc. (VIR) Presents at 2026 ASCO Genitourinary Cancers SymposiumSlideshow - Seeking Alpha
VIR Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
ARCH funds detail 8% Vir Biotechnology (NASDAQ: VIR) stake - Stock Titan
Insider Sell: Vicki Sato Sells 22,000 Shares of Vir Biotechnology Inc (VIR) - GuruFocus
Vir Biotechnology (NASDAQ:VIR) Director Vicki Sato Sells 22,000 Shares - MarketBeat
22,000 Vir Biotechnology (VIR) shares sold under 10b5-1 plan - Stock Titan
VIR (NASDAQ: VIR) files Form 144 for 88,000 pre-IPO shares - Stock Titan
Vir Biotechnology closes $172.5 million public offering of common stock - Investing.com South Africa
Vir Biotechnology Raises Capital Through Public Stock Offering - TipRanks
Vir Biotechnology closes $172.5 million public offering of common stock By Investing.com - Investing.com UK
Vir Biotechnology completes $172.5M follow-on offering, issues 20.29M shares - TradingView
[8-K] Vir Biotechnology, Inc. Reports Material Event | VIR SEC FilingForm 8-K - Stock Titan
Vir Biotechnology Astellas Deal Puts VIR-5500 And Valuation In Focus - Yahoo Finance
Vir Biotechnology (NASDAQ:VIR) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Watch Vir Bio CEO on Cancer Treatment Progress, Potential Deals - Bloomberg
Why Vir Biotechnology (VIR) Is Up 20.2% After Astellas Deal And $150 Million Equity Raise - simplywall.st
Insider Selling: Vir Biotechnology (NASDAQ:VIR) CFO Sells 1,634 Shares of Stock - MarketBeat
Brent Sabatini Sells 1,430 Shares of Vir Biotechnology (NASDAQ:VIR) Stock - MarketBeat
Mark Eisner Sells 1,616 Shares of Vir Biotechnology (NASDAQ:VIR) Stock - MarketBeat
Vir Biotechnology (NASDAQ:VIR) EVP Verneuil Vanina De Sells 3,117 Shares - MarketBeat
Vir Biotechnology Announces Significant Common Stock Offering - TipRanks
Vir Biotechnology Inc (VIR) 財務データ
収益
当期純利益
現金流量
EPS
1.82%
大文字化:
|
ボリューム (24 時間):